Exenatide (Exendin-4), a bioactive peptide composed of 39 amino acids, is antidiabetic medication acting as a long-acting glucagon-like peptide-1 receptor agonist with an IC50 of 3.22 nM.

PF-06291874 is a novel, highly potent glucagon receptor antagonist with favorable pharmacokinetics such as low in vivo clearance and excellent oral bioavailability in both rats and dogs.

BETP is a novel and potent PAM (positive allosteric modulator) and partial agonist of glucagon-like peptide-1 (GLP-1) receptor (EC50= 0.66 μM) with antidiabetic effects.

Exenatide acetate (Exendin-4 Acetate), a bioactive peptide composed of 39 amino acids, is antidiabetic medication acting as a long-acting glucagon-like peptide-1 receptor agonist with an IC50 of 3.22 nM.

Semaglutide TFA (NNC0113-0217; NNC-0113-0217), the trifluoroacetic acid salt form of semaglutide (brand name: Ozempic), is a human glucagon-like peptide-1 (GLP-1) analogue acting as a GLP-1 receptor agonist with longer duration of antidiabetic action.

GLP-1(7-37) acetate [also known as Tglp-1 and Insulinotropin], the acetate salt of GLP-1(7-37), is a novel insulinotropic hormone generated from the precursor peptide GLP-1 (1-37).

GLP-1(7-37) [also known as Tglp-1 and Insulinotropin] is a novel and potent insulinotropic hormone generated from the precursor peptide GLP-1 (1-37).

Avexitide [Exendin-3 (9-39)] is a novel, competitive and peptidic antagonist of glucagon-like peptide-1 (GLP-1) receptor with a Kd of 1.7 nM at cloned human GLP-1 receptors.

Lixisenatide acetate (AVE-0010; ZP-10A; Adlyxin; Lyxumia; ZP10A), the acetate salt of Lixisenatide, is a potent and short-acting agonist of the glucagon-like peptide-1 receptor (GLP-1R) approved in 2016 for the treatment of type 2 diabetes mellitus (T2DM).

Semaglutide acetate (NNC-0113-0217; NNC0113-0217), the acetic acid salt form of semaglutide (Ozempic), is a human glucagon-like peptide-1 (GLP-1) receptor agonist with longer duration of antidiabetic action.